Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8993948 | 0.94 | MAOA (0.43) | ADRA2CCARM1PRMT6PRMT8AOC3 | |
| SCHEMBL26782114 | 0.92 | CHRM2 (0.46) | ADRA2CCARM1PRMT6PRMT8AOC3 | |
| Iodide SCHEMBL10492775 | 0.92 | ADRA2C (0.42) | ADRA2CCARM1PRMT6PRMT8AOC3 | |
| SCHEMBL4395973 | 0.86 | CARM1 (0.52) | ADRA2CCARM1PRMT6PRMT8AOC3 | |
| SCHEMBL13645984 | 0.86 | SIGMAR1 (0.48) | AOC3CA12CA2CA9PPARG | |
| SCHEMBL11145951 | 0.86 | CA12 (0.47) | AOC3CA12CA2CA9PPARG | |
| Hydrochloric Acid SCHEMBL6890412 | 0.84 | CARM1 (0.50) | ADRA2CCARM1PRMT6PRMT8AOC3 | |
| SCHEMBL17037834 | 0.84 | SIGMAR1 (0.52) | AOC3CA12CA2CA9PPARG | |
| SCHEMBL29059909 | 0.83 | APP (0.53) | AOC3CA12CA2CA9PPARG | |
| SCHEMBL8643584 | 0.82 | CHRM2 (0.46) | CA12CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 317 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814451-B2 | Methods for preparing branched poly (2-hydroxyethyl methacrylate) at room temperature by inverse emulsion polymerization | Changzhou University (CN) | 2023-11-14 | — | — | US | claimed |
| US-20230018276-A1 | METHODS FOR PREPARING BRANCHED POLY (2-HYDROXYETHYL METHACRYLATE) AT ROOM TEMPERATURE BY INVERSE EMULSION POLYMERIZATION | Changzhou University (CN) | 2023-01-19 | — | — | US | claimed |
| US-11377508-B2 | Temperature-responsive poly(2-hydroxyethyl methacrylate) (PHEMA) and preparation method thereof | Changzhou University (CN) | 2022-07-05 | — | — | US | claimed |
| CN-111363083-B | Method for preparing branched polyhydroxyethyl methacrylate at room temperature by inverse emulsion polymerization | 常州大学 | 2022-02-11 | — | — | CN | claimed |
| CN-111393562-B | Temperature-responsive polyhydroxyethyl methacrylate and preparation method thereof | 常州大学 | 2021-04-30 | — | — | CN | claimed |
| CN-111393562-A | Temperature response type polyhydroxyethyl methacrylate and preparation method thereof | 常州大学 | 2020-07-10 | — | — | CN | claimed |
| CN-111363083-A | Method for preparing branched polyhydroxyethyl methacrylate at room temperature by inverse emulsion polymerization | 常州大学 | 2020-07-03 | — | — | CN | claimed |
| US-9737875-B2 | Affinity reagents for protein purification | IMPOSSIBLE FOODS INC. (US) | 2017-08-22 | — | — | US | claimed |
| CN-104620104-B | Affinity Reagents for Protein Purification | 非凡食品有限公司 | 2017-03-01 | — | — | CN | claimed |
| EP-1869053-B1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-ISOXAZOLO[4,5-C]PYRIDINE COMPOUNDS AND THEIR USE IN THE PRODUCTION OF MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2013-10-09 | — | — | EP | claimed |
| WO-2006094633-A1 | 1- SULFONYL-PI PERDINE- 3 -CARBOXYL I C ACID AMIDE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE FOR THE TREATMENT OF TYPE II DIABETES MELLITUS | F. HOFFMAN-LA ROCHE AG (CH) | 2006-09-14 | — | — | WO | claimed |
| US-6967216-B2 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2005-11-22 | — | — | US | claimed |
| EP-1401841-B1 | SUBSTITUTED 1-OXA-2,8-DIAZA-SPIRO 4,5]DEC-2-ENE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OF PAIN | GRUENENTHAL GMBH (DE) | 2005-08-24 | — | — | EP | claimed |
| EP-1458711-A1 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | claimed |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | claimed |
| WO-2003055877-A1 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER'S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | ASTRAZENECA AB (SE) | 2003-07-10 | — | — | WO | claimed |
| EP-1278739-A1 | AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR | AstraZeneca AB (SE) | 2003-01-29 | — | — | EP | claimed |
| US-20020058788-A1 | Facile deprotection of Fmoc protected amino groups | DISCOVERY PARTNERS INTERNATIONAL, INC. | 2002-05-16 | — | — | US | claimed |
| WO-2001085714-A1 | AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR | ASTRAZENECA AB (SE) | 2001-11-15 | — | — | WO | claimed |
| US-5710012-A | DETECTION OF CHOLESTEROL BY RELEASE OF HYDROGEN PEROXIDE | ACTIMED LABORATORIES, INC. (US) | 1998-01-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058788-A1 | Facile deprotection of Fmoc protected amino groups | DNPEP, LNPEP, NPEPPS | ADRA2C 4324/4885CARM1 367/4885PRMT6 34/4885 |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | NPY5R, NPY1R, NPY2R | ADRA2C 200/4885CARM1 2670/4885PRMT6 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.